| Rachel Coffin, LPN | |
|
314 Grove Neck Rd, Earleville, MD 21919-3008 | |
| (410) 275-6200 | |
| Not Available |
| Full Name | Rachel Coffin |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 314 Grove Neck Rd, Earleville, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295514693 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | LP53924 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Rachel Coffin, LPN 314 Grove Neck Rd, Earleville, MD 21919-3008 Ph: (410) 275-6200 | Rachel Coffin, LPN 314 Grove Neck Rd, Earleville, MD 21919-3008 Ph: (410) 275-6200 |
News Archive
"Low-quality and fake anti-malarial drugs flooding into markets in Asia and Africa are driving drug resistance and threatening gains made in the fight against the disease in the past decade, according to a study" conducted by researchers at the National Institutes of Health (NIH) and published Monday in the journal Lancet Infectious Diseases, Reuters reports.
In the first use of a framework allowing submission of a single application to the two agencies, the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) worked together to allow drug companies to submit the results of seven new tests that evaluate kidney damage during animal studies of new drugs. The tests measure the levels of seven key proteins or "biomarkers" found in urine that can provide additional information about drug-induced damage to kidney cells, also known as renal toxicity.
Bristol-Myers Squibb Company today reported results for the second quarter of 2010 which featured data on key marketed and investigational compounds in its oncology, diabetes and cardiovascular franchises, and growth in sales and EPS. The company also confirmed guidance for 2010 and minimum guidance for non-GAAP EPS in 2013.
IsoRay Inc., announced today a new dual therapy study using Cesium-131 brachytherapy (internal radiation therapy) and external beam radiation. Multiple sites have now received Institutional Review Board (IRB) approval for this study which will examine the efficacy of combining intensity modulated radiation (IMRT) with Cesium-131 brachytherapy to treat intermediate and high risk early stage prostate cancer.
› Verified 2 days ago
Ms. Tamya Smith, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 314 Grove Neck Rd, Earleville, MD 21919 Phone: 410-275-6241 Fax: 484-971-4896 | |
Shane Anderson, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 314 Grove Neck Rd, Earleville, MD 21919 Phone: 410-275-6200 | |
Ms. Danielle K Boyle, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 314 Grove Neck Rd, Earleville, MD 21919 Phone: 410-275-6200 | |
Calista Elias, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 314 Grove Neck Rd, Earleville, MD 21919 Phone: 410-275-6200 | |
Dayna A Walters, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 314 Grove Neck Rd, Earleville, MD 21919 Phone: 410-275-6200 Fax: 410-885-4041 | |
Samantha J Jarman, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 314 Grove Neck Rd, Earleville, MD 21919 Phone: 410-275-6200 |